Novo Nordisk: Wegovy® Study Shows Large Reductions in Heart Failure-Related Symptoms

Novo Nordisk’s (NYSE: NVO) Phase 3 STEP HFpEF trial demonstrated semaglutide 2.4 mg dose once-weekly led to large reductions in heart failure-related symptoms and physical limitations, improvements in exercise function, and greater weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.

Martin Lange, Executive Vice President and Head of Development at Novo Nordisk, said, “We are delighted with the results from STEP HFpEF, which show that semaglutide 2.4 mg is able to ease the disease burden for people with HFpEF and obesity in a substantial way.”

Highlights

The primary objective of STEP HFpEF trial was to investigate the effects of semaglutide 2.4 mg dosed once-weekly on symptoms, physical function, and body weight compared with placebo in patients with HFpEF and obesity.

The study included 529 people with symptomatic HFpEF and obesity, and measured two primary endpoints.

STEP HFpEF reduced subjects’ overall body weight, improved symptoms as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS), reduced inflammation and led to an increase in performance in the 6-Minute Walking Distance (6MWD) assessment.

The study’s findings have been presented at the European Society of Cardiology (ESC) Congress in the Netherlands and published in the New England Journal of Medicine.

HFpEF comprises roughly half of all heart failure cases and is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise, and swelling of extremities.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Share This Article

 

About the Author

Novo Nordisk: Wegovy® Study Shows Large Reductions in Heart Failure-Related Symptoms

Editor Prism MarketView